Hangzhou Tigermed Technology Co., Ltd. is a prominent Chinese contract research organization specializing in comprehensive clinical trial services for pharmaceutical research and development. Established with the aim of facilitating medical R&D, Tigermed helps clients mitigate risks and costs associated with bringing new products to market. The company operates 21 subsidiaries across 43 cities worldwide, including major regions in China, North America, Japan, Australia, and Korea, and employs a skilled team of over 900 professionals who adhere to international operational standards. Tigermed offers a range of services, including bioanalytical testing, medical writing, biostatistics analysis, and medical imaging, with a focus on various therapeutic areas such as infections, hematology, cardiovascular diseases, endocrinology, rheumatology, nephrology, and central nervous system disorders. By the end of 2013, Tigermed had successfully provided clinical trial services to over 300 clients and participated in the development of multiple domestic drugs, earning recognition as an "Innovation-type CRO."
ta management and monitoring for all human studies
Bivision
Series A in 2024
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Marti Farm
Acquisition in 2023
Marti Farm is a contract research organization that provides specialized research and consultancy services to the healthcare, pharmaceutical, biotechnology, food supplement, and cosmetics industries. The company focuses on developing and delivering health-improving outcomes, working closely with clients to meet their specific needs. Through its expertise, Marti Farm aims to facilitate advancements in health-related products and services, contributing to the overall improvement of public health.
Hipower
Series B in 2022
Hipower is a clinical CRO company that helps with drug research and development. After listing them, they reconsidered pharmaceuticals, stem cells, genetic medications, medical gadgets, and other disciplines, such as large-scale variety culture, secondary development of traditional medicine, and research.
LTZ Therapeutics
Seed Round in 2022
LTZ Therapeutics is engaged in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. The company employs reverse translational science and tumor biology, integrating these approaches with machine learning to advance its immunotherapy solutions. This strategy enables LTZ Therapeutics to create novel cancer treatments that address significant unmet clinical needs, ultimately striving to improve patient outcomes in the field of oncology.
BioInno
Series A in 2021
BioInno is a China-based company that specializes in biopharmaceutical contract development and manufacturing organization (CDMO) services. It focuses on process development and Good Manufacturing Practice (GMP) production for biotechnology and pharmaceutical companies seeking to introduce protein, cell therapy, and gene therapy drugs to both the Chinese and global markets. By offering comprehensive outsourcing solutions, BioInno supports clients in the complex development and production processes necessary for bringing innovative therapies to market.
Jisi Yingda
Series B in 2021
Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.
CytoLynx Therapeutics
Funding Round in 2021
CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.
Adlai Nortye
Series D in 2021
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative cancer therapies and treatments for metabolic diseases. Founded in 2004 and based in Hangzhou, China, the company has established research and development and clinical operations in both China and the United States. Adlai Nortye has a diverse pipeline of over ten drug candidates, including several in various stages of clinical development, such as buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside preclinical candidates like AN8025, AN9025, and AN1025. The company emphasizes collaborations and internal discoveries to advance its strategic focus on oncology.
Gmax Biopharm
Series C in 2021
Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. Gmax Biopharm develops a proprietary platform with a systemic approach to GPCR MAb generation, screening, and development. Gmax Biopharm enables antibody screening, humanization, and engineering to produce antibody candidates with high drugability and developability.
3D Medicines
Venture Round in 2020
3D Medicines is a biopharmaceutical company focused on the research, development, and commercialization of personalized treatments for cancer. By utilizing individuals' genetic information, the company aims to enhance the prevention, diagnosis, and management of cancer as a chronic disease. 3D Medicines specializes in creating differentiated immuno-oncology drugs designed to improve patient outcomes, extending both survival time and quality of life for those affected by cancer. The company generates its revenue exclusively from the Chinese market.
Hinova Pharma
Series C in 2020
Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.
Adlai Nortye
Series C in 2020
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative cancer therapies and treatments for metabolic diseases. Founded in 2004 and based in Hangzhou, China, the company has established research and development and clinical operations in both China and the United States. Adlai Nortye has a diverse pipeline of over ten drug candidates, including several in various stages of clinical development, such as buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside preclinical candidates like AN8025, AN9025, and AN1025. The company emphasizes collaborations and internal discoveries to advance its strategic focus on oncology.
Asieris Pharmaceuticals
Series C in 2020
Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.
CANbridge Pharmaceuticals
Series D in 2020
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
EOC Pharma Group
Series C in 2019
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
LaNova Medicines
Angel Round in 2019
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Yaxincheng
Venture Round in 2019
Yaxincheng specializes in medical device and pharmaceutical translation services tailored for the life sciences sector. Based in China, the company offers translation of a wide range of documents, including those related to research, registration, marketing, training, and management of drugs, medical devices, biological products, and vaccines. Yaxincheng provides language support in multiple pairs, including Chinese, English, Japanese, German, and French, among others, ensuring effective communication across diverse linguistic needs in the healthcare industry.
CMAB BioPharm
Series B in 2018
CMAB BioPharm is a biopharmaceutical service firm based in Suzhou, China, specializing in process development and manufacturing services for biologic products. Established in 2017, the company offers customized development and manufacturing solutions for antibodies and biologics, catering to both domestic and international clients. CMAB BioPharm's services include process development, GMP manufacturing, and the production of aseptic drug products, adhering to stringent quality standards. The firm supports its customers through all stages of drug development, providing comprehensive solutions for preclinical and clinical phases, from initial DNA sequences to commercial production.
Collietech
Corporate Round in 2018
Collietech is a Chinese provider of electronic Common Technical Document (eCTD) software and services, primarily serving the life sciences sector. The company specializes in developing eCTD software tailored for the medical industry, with its flagship product being the first self-developed eCTD series software in China. This software assists pharmaceutical companies in registering and declaring their drug products for international sales, facilitating compliance with regulatory requirements in foreign markets. Through its innovative solutions, Collietech aims to enhance the efficiency and accuracy of the drug approval process for its clients.
MED.CIRCLE
Angel Round in 2017
MED.CIRCLE is a medical information service company. It is a service platform that can support many medical academic activities. Their services include medical academic activities and medical device innovation incubation.
Yaxincheng
Angel Round in 2017
Yaxincheng specializes in medical device and pharmaceutical translation services tailored for the life sciences sector. Based in China, the company offers translation of a wide range of documents, including those related to research, registration, marketing, training, and management of drugs, medical devices, biological products, and vaccines. Yaxincheng provides language support in multiple pairs, including Chinese, English, Japanese, German, and French, among others, ensuring effective communication across diverse linguistic needs in the healthcare industry.
NovaSignal
Series A in 2015
NovaSignal Corporation is a medical device company that specializes in the research, development, and manufacturing of advanced diagnostic systems for brain health management. Founded in 2013 and based in Los Angeles, California, with a location in Bengaluru, India, NovaSignal's key products include the Lucid robotic system and the Lucid M1 system. These innovative devices utilize a combination of non-invasive ultrasound, robotics, and artificial intelligence to facilitate the early detection of conditions such as stroke, trauma, and dementia by analyzing real-time cerebral blood flow. The company's technology enables clinicians to accurately assess brain health by automatically adjusting the orientation and position of the device to capture critical data. Formerly known as Neural Analytics, Inc., the company rebranded to NovaSignal Corporation in July 2020.
DreamCIS
Acquisition in 2015
DreamCIS Inc., established in 2000 and headquartered in Seoul, South Korea, specializes in clinical research services. The company offers a comprehensive range of services including clinical development, biostatistics, data management, pharmacovigilance, medical writing, site startup, clinical monitoring, quality assurance, and regulatory consulting for pharmaceuticals and medical devices. DreamCIS caters to clients such as pharmaceutical companies, bio ventures, and medical device manufacturers, providing professional support throughout the drug development and clinical trial processes. The company is committed to maintaining high-quality standards through scientific and systematic approaches, ensuring ethical practices in its operations.
Yijiayi
Series A in 2015
Yijiayi have treatment methods for cancer patients such as surgery, radiotherapy, and chemotherapy can result in toxic and side effects such as dry mouth, nausea and vomiting, diarrhea, and constipation, as psychological factors such as depression and anxiety, which can affect the patient's appetite and eating habits of nutritional deficiencies in cancer patients.
Frontage Laboratories
Acquisition in 2014
Frontage Holdings Corporation is a contract research organization that offers a comprehensive range of research, analytical, and development services to pharmaceutical, biotechnology, and agrochemical companies. Established in 2018 and headquartered in Exton, Pennsylvania, the company supports drug discovery and development through services such as drug metabolism, pharmacokinetics, safety and toxicology, and bioanalytical testing. Additionally, Frontage provides product development and bioequivalence services that assist generic and consumer health pharmaceutical firms in their regulatory submissions. With operations in North America, including the United States and Canada, as well as in the People's Republic of China and other global markets, Frontage Holdings aims to facilitate the advancement of biopharmaceutical research and development from early stages to late-stage clinical trials. The company is a subsidiary of Hong Kong Tigermed Co., Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.